Derived from a novel chemistry platform and cell-based differential screening, our technology targets cancer while protecting healthy cells.
Onconova is focused on discovering and developing novel products to treat cancer.
Onconova Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing products to treat cancer.
Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova currently has a pre-IND stage program with a CDK4/6 and Ark5 inhibitor, ON 123300.
Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.
We were deeply saddened by the passing of Dr. James Holland,
a distinguished member of our advisory board since 2004.
Dr. Holland passed away on March 22, 2018.
http://www.legacy.com/obituaries/name/james-holland-obituary?pid=188530957&view=guestbook&page=2
Onconova Therapeutics News Releases
